Are you up to date on the current optimal management of β-thalassemia?
Are you prepared to use the newly approved erythroid maturation agent luspatercept in the care of your adult patients with transfusion-dependent β-thalassemia?
Read expert answers to key audience questions from a recent symposium on optimal management of patients with β-thalassemia.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.